STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA

STAT PlusBiotech BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA Manage alerts for this article Email this article Share this article By Adam Feuerstein, Matthew Herper, and Angus ChenMay 30, 2026 Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.Matthew Herper[email protected]Matthew Herper covers medical innovation — both its promise and its perils.Angus Chen[email protected]Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08. You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. A huge thanks to everyone who attended the jam-packed STAT @ ASCO event last night. The bao buns were incredible. IYKYK.Advertisement Don’t forget to sign up for our ASCO virtual recap on Wednesday. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In ASCO, Cancer, drug development, FDA, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Matthew Herper Senior Writer, Medicine, Editorial Director of Events Matthew Herper covers medical innovation — both its promise and its perils. Angus Chen Cancer Reporter Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech May 31, 2026 STAT Plus: A standing ovation for RevMed, and caution for Akeso Pharma May 31, 2026 Ultra-low doses could bring costly cancer treatments to more patients in poorer countries Advertisement Biotech May 31, 2026 STAT Plus: Practice-changing results reported for Revolution Medicines pancreatic cancer drug Biotech May 31, 2026 STAT Plus: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer Biotech May 31, 2026 STAT Plus: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds Subscriber Picks